Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,676 public trials 321 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Infirmary Health - Diagnostic & Medical Clinic (DMC) Mobile, Alabama, United States
  • Chao Family Comprehensive Cancer Center UCI Orange, California, United States
  • University of Kansas Westwood, Kansas, United States
  • University of Maryland | Greenebaum Cancer Center Baltimore, Maryland, United States
View all 56 locations
View Trial Details
Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

NCT07637578

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Willamette Valley Cancer Institute and Research Center Eugene, Oregon, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
View Trial Details
Recruiting

RAT-HEMATO : Return to Work After Malignant Hemopathy

NCT06262789

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • Angers University hospital Angers, France
  • Brest University Hospital, Morvan Site Brest, France
  • Caen University hospital Caen, France
  • Rennes University Hospital, Pontchaillou site Rennes, France
View Trial Details
Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
  • CHU Lyon Sud - Service Hématologie Pierre-Bénite, France
  • IUCT Oncopole Toulouse, France
View all 16 locations
View Trial Details
Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Yale New Haven Hospital-Smilow Cancer Center New Haven, Connecticut, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 22 locations
View Trial Details
Recruiting

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

NCT05272826

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • NL Health Services St. John's, Newfoundland and Labrador, Canada
  • QEII Health Science Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
View Trial Details
Recruiting

Elranatamab in R/R Multiple Myeloma

NCT06138275

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details

Related conditions